Vir Biotechnology, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VIR Nasdaq 2830 www.vir.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vir Biotechnology, Inc.

Is Vir Biotechnology (VIR) Undervalued On Its Gilead Oncology Deal? - Oct 26th, 2026 6:19 pm
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results - Oct 21st, 2026 2:05 pm
Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News? - Oct 17th, 2026 5:10 am
Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts - Oct 16th, 2026 5:57 pm
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Oct 15th, 2026 11:17 am
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers - Oct 15th, 2026 8:30 am
What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership? - Oct 14th, 2026 11:09 am
Vir Biotechnology, Gilead Sciences to Develop Dual-Masked T-Cell Engagers for Solid Tumors - Oct 14th, 2026 7:22 am
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors - Oct 14th, 2026 6:30 am
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer - Oct 8th, 2026 6:30 am
How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative - Oct 8th, 2026 12:13 am
Vir Biotechnology Appoints David Liu as Chief Medical Officer - Oct 7th, 2026 6:30 am
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 - Oct 5th, 2026 2:05 pm
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer - Oct 1st, 2026 6:30 am
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Aug 31st, 2026 2:05 pm
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - Aug 12th, 2026 3:28 pm
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Aug 6th, 2026 6:30 am
Vir Biotechnology Q2 Earnings Call Highlights - Aug 6th, 2026 1:03 am